GATA3 Expression in Breast Carcinoma: Associations with Clinicopathological Features
Abstract
Background: Breast carcinoma is a heterogeneous disease, morphologically and molecularly. GATA binding protein 3 (GATA3) is an important marker in breast cancer origin. GATA3 expression and its prognostic value in breast carcinoma are inconsistent. Tumor budding is a small cluster of malignant cells in the invasive edge of the tumor. Breast carcinoma with highgrade tumor budding has an unfavorable prognosis. The objective of this study was to determine whether there is a relationship between GATA3 expression and clinicopathological parameters in breast carcinoma including with tumor budding grade. Another objective of this study was to determine the association between GATA3 expression and other clinicopathological factors with nodal status.
Methods: This was a cross-sectional study involving breast carcinoma patients at Prof. Dr. I.G.N.G Ngoerah Hospital during the year 2022 who underwent mastectomy and axillary node dissection. GATA3 expression was determined by immunohistochemistry and categorized into weak and strong expression. Tumor budding was evaluated in Hematoxylin & Eosin slides and categorized into low and high grades. The association between GATA3 expressions and clinicopathological parameters, and the association between GATA3 expression and clinicopathological parameters with nodal status, were assessed with a chi-square test with a significance level determined at p < 0.05.
Results: There were 61 breast carcinoma patients with mastectomy and axillary node dissection that fulfilled inclusion and exclusion criteria. GATA3 expression was significantly associated with the histological type (p = 0.012) and molecular subtype (p < 0.001) of the tumor. There was an association between nodal status and molecular subtype of tumor (p = 0.012), tumor stage (p = 0.005), and tumor budding grade (p = 0.024), but there was no association between GATA3 expression and nodal status (p = 0.066).
Conclusion: GATA3 expression is associated with the histological type and molecular subtype of tumor in breast carcinoma, but not with nodal status. Nodal status was associated with molecular subtype, T stage, and tumor budding grade of tumor.
Keywords
DOI: 10.33371/ijoc.v18i4.1183
Article Metrics
Abstract View: 352, 
PDF Download: 99
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.
Johansson ALV, Trewin CB, Fredriksson I, Reinertsen K V., Russnes H, Ursin G. In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study. Breast Cancer Research. 2021;23:1–10.
Naylor MJ, Ormandy CJ. Gata-3 and mammary cell fate. Breast Cancer Research. 2007;9:2–3.
Afzaljavan F, Sadr AS, Savas S, Pasdar A. GATA3 somatic mutations are associated with clinicopathological features and expression profile in TCGA breast cancer patients. Sci Rep. 2021;11:1–13.
Liu H, Shi J, Wilkerson ML, Lin F. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: A useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol. 2012;138:57–64.
McCleskey BC, Penedo TL, Zhang K, Hameed O, Siegal GP, Wei S. GATA3 expression in advanced breast cancer: Prognostic value and organ-specific relapse. Am J Clin Pathol. 2015;144:756–63.
Yildirim E, Bektas S, Gundogar O, Findik D, Alcicek S, Erdogan KO, et al. The relationship of GATA3 and Ki-67 with histopathological prognostic parameters, locoregional recurrence and disease-free survival in invasive ductal carcinoma of the breast. Anticancer Res. 2020;40:5649–57.
Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Modern Pathology. 2017;30:1299–311.
Sriwidyani NP, Manuaba IBTW, Alit-Artha IG, Mantik-Astawa IN. Tumor Budding in Breast Carcinoma: Relation to E-Cadherin, MMP-9 Expression, and Metastasis Risk. Bali Medical Journal. 2016;5:150.
Huang T, Bao H, Meng Y hua, Zhu J lin, Chu X dong, Chu X li, et al. Tumour budding is a novel marker in breast cancer: the clinical application and future prospects. Ann Med. 2022;54:1303–12.
Nguyen D, Yu J, Reinhold WC, Yang SX. Association of Independent Prognostic Factors and Treatment Modality with Survival and Recurrence Outcomes in Breast Cancer. JAMA Netw Open. 2020;3:1–11.
Min SK, Lee SK, Woo J, Jung SM, Ryu JM, Yu J, et al. Relation between tumor size and lymph node metastasis according to subtypes of breast cancer. J Breast Cancer. 2021;24:75–84.
Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015;5:2929–43.
Yang SX, Hewitt SM, Yu J. Locoregional tumor burden and risk of mortality in metastatic breast cancer. NPJ Precis Oncol. 2022;6:1–7.
Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022;12:31–46.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Email this article 
